September 30, 2021
Thursday | 16:00 - 19:00 (GMT+3)
Session: COVID-19 and Rare Diseases (part I) 16:00 – 17:15 Moderators: | |
---|---|
16:00-16:03 | Welcome Lina Kryžauskaitė, MD |
16:03-16:05 | Intro Sonata Šaulytė Trakymienė MD, PhD |
16:05–16:35 | Vaccine-Induced Immune Thrombocytopenia and Thrombosis |
16:35-16:50 | SARS-CoV-2 Vaccine Induced Antibody Responses in Oncohematological Patients Kazimieras Maneikis, MD, Vilnius University Hospital Santaros Klinikos, Lithuania |
16:50-17:05 | Role of Biobanking in Rare and Newly Emerged Disease Daniel Naumovas, Vilnius University Hospital Santaros Klinikos, Lithuania |
17:05–17:15 | Discussion |
17:15–17:30 | Break |
Session: COVID-19 and Rare Diseases (part II) 17:30 – 19:05 Moderators: | |
---|---|
17:30 - 17:35 | Intro Jelena Rascon, MD, PhD, Vilnius University Hospital Santaros Klinikos, Lithuania |
17:35-17:50 | Bioinformatics in the Diagnosis of Inherited Predisposition to Hematological Disease |
17:50-18:20 | Hemophagocytic lymphohistiocytosis: Primary or Secondary? |
18:20-18:50 | The Challenges of TMA: Posttransplant TTP / aHUS |
18:50-19:05 | Discussion |
October 1, 2021
Friday | 15:40 - 20:00 (GMT+3)
Session: Acute Myeloid Leukemia 15:40 – 17:00 Moderators: | |
---|---|
15:40-15:45 | Intro Andrius Žučenka, MD, Vilnius University Hospital Santaros Klinikos, Lithuania |
15:45-16:25 | Changing Diagnosis and Treatment Paradigm in AML Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center, USA |
16:25-16:45 | Targeted Therapy in Relapsed/Refractory AML |
16:45-17:00 | Discussion |
17:00-17:15 | Break |
Session: The Challenge of Multiresistant Pathogens 17:15 – 18:20 Moderators: | |
---|---|
17:15-17:20 | Intro |
17:20–17:50 | Challenges of Multiresistant Infections after Intesive Therapy Matteo Bassetti, MD, PhD, Policlinico San Martino University Hospital, Genoa, Italy |
17:50-18:05 | Genetic Evolution of SARS-CoV-2 Virus in Hematology Patients with Chronic Active COVID-19 Dovilė Juozapaitė, Vilnius University Hospital Santaros Klinikos, Lithuania |
18:05-18:20 | Discussion |
18:30–20:00 | Virtual Poster Exhibition |
October 2, 2021
Saturday | 10:00 – 16:10 (GMT+3)
Session: Multiple Myeloma and Lymphoproliferative Disorders 10:00 – 13:00 Moderators: | |
---|---|
10:00–10:05 | Intro Valdas Pečeliūnas, MD, PhD, Vilnius University Hospital Santaros klinikos, Lithuania |
10:05–10:35 | Best Affordable Treatment for Multiple Myeloma Maria Victoria Mateos Manteca, MD, PhD, Department of Hematology, Hospital Clinico Universitario, Spain |
10:35-10:50 | Autologous HSCT for Multiple Myeloma with Renal Impairment |
10:50-11:05 | Estonian myeloma audit (treatment and outcomes over 5 years) Dr. Mari Punab, Tartu Ülikooli Kliinikum, Estonia |
11:05-11:10 | Discussion |
11:10-11:40 | Relapsed/Refractory Diffuse Large B Cell Lymphoma: Current Treatment Options |
11:40-12:00 | AITL: It's face is not the issue Lukas Kevličius, MD, Ugnius Mickys, MD, Vilnius University Hospital Santaros klinikos, Lithuania |
12:00-12:15 | Discussion |
12:15-13:00 | Break |
Session: Hematopoietic Stem Cell Transplantation. Cell Therapies. 13:00 – 16:30 Moderators: | |
---|---|
13:00–13:05 | Intro Artūras Slobinas, MD, Vilnius University Hospital Santaros Klinikos, Lithuania |
13:05–13:20 | 20 Years of Allogeneic HSCT Experience in Lithuania Rita Čekauskienė, MD, Vilnius University Hospital Santaros Klinikos, Lithuania |
13:20–13:35 | 20 Years of Autologous HSCT Experience in Lithuania Valdas Pečeliūnas, MD, Vilnius University Hospital Santaros Klinikos, Lithuania |
13:35–13:50 | Allogeneic and Autologous HSCT Experience in Estonia Ain Kaare, MD, Tartu University Hospital Foundation, Estonia |
13:50-14:05 | Autologous Stem Cell Transplantation for Primary Central Nervous System Lymphoma |
14:05-14:20 | Role of Non-Myeloablative Conditioning in SAA Treatment Domas Vaitiekus, MD, PhD, Hospital of Lithuanian University of Health Sciences Kauno Klinikos, Lithuania |
14:20-14:35 | Discussion |
14:35-14:50 | Break |
Session: Hematopoietic Stem Cell Transplantation. Cell Therapies (part II) 14:50 – 16:30 Moderators: Artūras Slobinas, MD (Vilnius University Hospital Santaros Klinikos, Lithuania) | |
---|---|
14:50 -14:55 | Intro Adomas Bukauskas, MD, Vilnius University Hospital Santaros Klinikos, Lithuania |
14:55-15:10 | HSCT for Multiple Sclerosis: A Neurologist’s Perspective Nataša Giedraitienė, MD, PhD, Valdas Pečeliūnas, MD, PhD, Vilnius University Hospital Santaros Klinikos, Lithuania |
15:10-15:25 | Mesenchymal Cell Therapy Adomas Bukauskas, MD, Vilnius University Hospital Santaros Klinikos, Lithuania |
15:25-15:40 | Virus-specific T-cell Therapy |
15:40-16:10 | Chimeric Antigen Receptor T-cell Toxicity Sattva S Neelapu, MD, The University of Texas MD Anderson Cancer Center, USA |
16:10-16:15 | Discussion |
16:15-16:30 | Congress Closing Remarks Lina Kryžauskaitė, Lithuania Sandra Lejniece, Latvia Mariken Ross, Estonia |
Parallel Session: Pediatric and AYA Hematology and Oncology 2021-10-01 Friday 12:00 – 16:00 |
Parallel Session: Nurse Session View agenda -> press HERE |
Education Lecture More information HERE |